1
|
Abstract
Restless legs syndrome (RLS) is a common sensorimotor disorder characterized by an urge to move that appears during rest or is exacerbated by rest, that occurs in the evening or night and that disappears during movement or is improved by movement. Symptoms vary considerably in age at onset, frequency and severity, with severe forms affecting sleep, quality of life and mood. Patients with RLS often display periodic leg movements during sleep or resting wakefulness. RLS is considered to be a complex condition in which predisposing genetic factors, environmental factors and comorbidities contribute to the expression of the disorder. RLS occurs alone or with comorbidities, for example, iron deficiency and kidney disease, but also with cardiovascular diseases, diabetes mellitus and neurological, rheumatological and respiratory disorders. The pathophysiology is still unclear, with the involvement of brain iron deficiency, dysfunction in the dopaminergic and nociceptive systems and altered adenosine and glutamatergic pathways as hypotheses being investigated. RLS is poorly recognized by physicians and it is accordingly often incorrectly diagnosed and managed. Treatment guidelines recommend initiation of therapy with low doses of dopamine agonists or α2δ ligands in severe forms. Although dopaminergic treatment is initially highly effective, its long-term use can result in a serious worsening of symptoms known as augmentation. Other treatments include opioids and iron preparations.
Collapse
|
2
|
Park KT, Sim I, Ko HS, Lim YH. Gamma Aminobutyric Acid Increases Absorption of Glycine-Bound Iron in Mice with Iron Deficiency Anemia. Biol Trace Elem Res 2020; 197:628-638. [PMID: 31927755 DOI: 10.1007/s12011-020-02027-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/20/2019] [Accepted: 01/01/2020] [Indexed: 11/30/2022]
Abstract
Iron deficiency is a leading cause of anemia. Amino acids are known to promote the absorption of both soluble and insoluble iron. The bioavailability of organic iron is higher than that of inorganic iron. Therefore, the aim of this study was to evaluate the iron absorption of glycine-bound iron (an organic iron) and a combination of glycine-bound iron and gamma aminobutyric acid (GABA) in mice with iron deficiency anemia (IDA). Mice were fed an iron-deficient diet for 3 weeks, followed by oral administration of GABA, inorganic iron, glycine-bound iron, or GABA plus glycine-bound iron for 5 weeks. Ferritin storage in the spleen was measure by immunohistochemistry (IHC). Iron deposition in the liver and spleen tissues was analyzed using atomic absorption spectrometry. Expression levels of iron absorption-related genes were measured by quantitative real-time polymerase chain reaction (qPCR). Iron absorption was enhanced in the glycine-bound iron-treated group compared with the inorganic iron-treated group. Hemoglobin, serum Fe, ferritin, and liver iron levels did not increase in mice treated with GABA alone. However, mice administered GABA in combination with glycine-bound iron showed higher iron absorption than those administered organic iron alone. Our results indicate that glycine-bound iron in combination with GABA might exert a synergistic effect on iron absorption and bioavailability, suggesting that the addition of GABA to existing iron supplements might increase their effectiveness for treating IDA.
Collapse
Affiliation(s)
- Keun-Tae Park
- Research and Development Center, Milae Bioresources Co. Ltd., Seoul, 05542, Republic of South Korea
- Department of Integrated Biomedical and Life Sciences, College of Health Science, Korea University, Seoul, 02841, Republic of South Korea
| | - Insuk Sim
- Department of Integrated Biomedical and Life Sciences, College of Health Science, Korea University, Seoul, 02841, Republic of South Korea
| | - Hyun-Soo Ko
- Department of Integrated Biomedical and Life Sciences, College of Health Science, Korea University, Seoul, 02841, Republic of South Korea
| | - Young-Hee Lim
- Department of Integrated Biomedical and Life Sciences, College of Health Science, Korea University, Seoul, 02841, Republic of South Korea.
- Department of Public Health Science (Brain Korea 21 PLUS program), Graduate School, Korea University, Seoul, 02841, Republic of South Korea.
- Department of Laboratory Medicine, Korea University Guro Hospital, Seoul, 08308, Republic of South Korea.
| |
Collapse
|
3
|
Lanza G, Ferri R. The neurophysiology of hyperarousal in restless legs syndrome: Hints for a role of glutamate/GABA. ADVANCES IN PHARMACOLOGY (SAN DIEGO, CALIF.) 2019; 84:101-119. [PMID: 31229167 DOI: 10.1016/bs.apha.2018.12.002] [Citation(s) in RCA: 46] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Restless legs syndrome (RLS) is a common sensory-motor circadian disorder, whose basic components include urge to move the legs, unpleasant sensory experience, and periodic leg movements during sleep, all associated with an enhancement of the individual's arousal state. Brain iron deficiency (BID) is considered to be a key initial pathobiological factor, based on alterations of iron acquisition by the brain, also moderated by genetic factors. In addition to the well-known dopaminergic involvement in RLS, previous studies pointed out that BID brings also a hyperglutamatergic state that influences a dysfunctional cortico-striatal-thalamic-cortical circuit in genetically vulnerable individuals. However, the enhancement of arousal mechanisms in RLS may also be explained by functional changes of the ascending arousal systems and by deficitary GABA-mediated inhibitory control. Very recently, it was also suggested that BID induces a hypoadenosinergic state in RLS, thus possibly providing a link for a putative unified pathophysiological mechanism accounting for both hyperarousal and sensory-motor signs. Consequently, RLS might be viewed as a multitransmitter neurochemical disorder, globally resulting in enhanced excitability and decreased inhibition. In this framework, understanding the complex interaction of different neuronal circuits in generating the symptoms of RLS is mandatory both for a better diagnostic refinement and for an innovative therapeutic support. Notably, multiple neurotransmission dysfunction, either primary or triggered by BID, may also bridge the gap between RLS and other chronic pain disorders. This chapter summarizes the current experimental and clinical findings into a heuristic model of the electrophysiology and neurochemistry underlying RLS.
Collapse
|
4
|
Nuñez MT, Chana-Cuevas P. New Perspectives in Iron Chelation Therapy for the Treatment of Neurodegenerative Diseases. Pharmaceuticals (Basel) 2018; 11:ph11040109. [PMID: 30347635 PMCID: PMC6316457 DOI: 10.3390/ph11040109] [Citation(s) in RCA: 94] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2018] [Revised: 07/31/2018] [Accepted: 08/03/2018] [Indexed: 02/07/2023] Open
Abstract
Iron chelation has been introduced as a new therapeutic concept for the treatment of neurodegenerative diseases with features of iron overload. At difference with iron chelators used in systemic diseases, effective chelators for the treatment of neurodegenerative diseases must cross the blood–brain barrier. Given the promissory but still inconclusive results obtained in clinical trials of iron chelation therapy, it is reasonable to postulate that new compounds with properties that extend beyond chelation should significantly improve these results. Desirable properties of a new generation of chelators include mitochondrial destination, the center of iron-reactive oxygen species interaction, and the ability to quench free radicals produced by the Fenton reaction. In addition, these chelators should have moderate iron binding affinity, sufficient to chelate excessive increments of the labile iron pool, estimated in the micromolar range, but not high enough to disrupt physiological iron homeostasis. Moreover, candidate chelators should have selectivity for the targeted neuronal type, to lessen unwanted secondary effects during long-term treatment. Here, on the basis of a number of clinical trials, we discuss critically the current situation of iron chelation therapy for the treatment of neurodegenerative diseases with an iron accumulation component. The list includes Parkinson’s disease, Friedreich’s ataxia, pantothenate kinase-associated neurodegeneration, Huntington disease and Alzheimer’s disease. We also review the upsurge of new multifunctional iron chelators that in the future may replace the conventional types as therapeutic agents for the treatment of neurodegenerative diseases.
Collapse
Affiliation(s)
- Marco T Nuñez
- Faculty of Sciences, Universidad de Chile, Las Palmeras 3425, Santiago 7800024, Chile.
| | - Pedro Chana-Cuevas
- Center for the Treatment of Movement Disorders, Universidad de Santiago de Chile, Belisario Prat 1597, Santiago 83800000, Chile.
| |
Collapse
|
5
|
Ferré S, García-Borreguero D, Allen RP, Earley CJ. New Insights into the Neurobiology of Restless Legs Syndrome. Neuroscientist 2018; 25:113-125. [PMID: 30047288 DOI: 10.1177/1073858418791763] [Citation(s) in RCA: 72] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Restless legs syndrome (RLS) is a common sensorimotor disorder, whose basic components include a sensory experience, akathisia, and a sleep-related motor sign, periodic leg movements during sleep (PLMS), both associated with an enhancement of the individual's arousal state. The present review attempts to integrate the major clinical and experimental neurobiological findings into a heuristic pathogenetic model. The model also integrates the recent findings on RLS genetics indicating that RLS has aspects of a genetically moderated neurodevelopmental disorder involving mainly the cortico-striatal-thalamic-cortical circuits. Brain iron deficiency (BID) remains the key initial pathobiological factor and relates to alterations of iron acquisition by the brain, also moderated by genetic factors. Experimental evidence indicates that BID leads to a hyperdopaminergic and hyperglutamatergic states that determine the dysfunction of cortico-striatal-thalamic-cortical circuits in genetically vulnerable individuals. However, the enhanced arousal mechanisms critical to RLS are better explained by functional changes of the ascending arousal systems. Recent experimental and clinical studies suggest that a BID-induced hypoadenosinergic state provides the link for a putative unified pathophysiological mechanism for sensorimotor signs of RLS and the enhanced arousal state.
Collapse
Affiliation(s)
- Sergi Ferré
- 1 National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA
| | | | - Richard P Allen
- 3 Department of Neurology, Johns Hopkins University, Baltimore, MD, USA
| | | |
Collapse
|
6
|
Aguirre P, García-Beltrán O, Tapia V, Muñoz Y, Cassels BK, Núñez MT. Neuroprotective Effect of a New 7,8-Dihydroxycoumarin-Based Fe 2+/Cu 2+ Chelator in Cell and Animal Models of Parkinson's Disease. ACS Chem Neurosci 2017; 8:178-185. [PMID: 27806193 DOI: 10.1021/acschemneuro.6b00309] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
Disturbed iron homeostasis, often coupled to mitochondrial dysfunction, plays an important role in the progression of common neurodegenerative diseases such as Parkinson's disease (PD). Recent studies have underlined the relevance of iron chelation therapy for the treatment of these diseases. Here we describe the synthesis, chemical, and biological characterization of the multifunctional chelator 7,8-dihydroxy-4-((methylamino)methyl)-2H-chromen-2-one (DHC12). Metal selectivity of DHC12 was Cu2+ ∼ Fe2+ > Zn2+ > Fe3+. No binding capacity was detected for Hg2+, Co2+, Ca2+, Mn2+, Mg2+, Ni2+, Pb2+, or Cd2+. DHC12 accessed cells colocalizing with Mitotracker Orange, an indication of mitochondrial targeting. In addition, DHC12 chelated mitochondrial and cytoplasmic labile iron. Upon mitochondrial complex I inhibition, DHC12 protected plasma membrane and mitochondria against lipid peroxidation, as detected by the reduced formation of 4-hydroxynonenal adducts and oxidation of C11-BODIPY581/591. DHC12 also blocked the decrease in mitochondrial membrane potential, detected by tetramethylrhodamine distribution. DHC12 inhibited MAO-A and MAO-B activity. Oral administration of DHC12 to mice (0.25 mg/kg body weight) protected substantia nigra pars compacta (SNpc) neurons against MPTP-induced death. Taken together, our results support the concept that DHC12 is a mitochondrial-targeted neuroprotective iron-copper chelator and MAO-B inhibitor with potent antioxidant and mitochondria protective activities. Oral administration of low doses of DHC12 is a promising therapeutic strategy for the treatment of diseases with a mitochondrial iron accumulation component, such as PD.
Collapse
Affiliation(s)
- Pabla Aguirre
- Biology
Department, Faculty of Sciences, Universidad de Chile, Santiago 7800024, Chile
| | - Olimpo García-Beltrán
- Facultad
de Ciencias Naturales y Matemáticas, Universidad de Ibagué, Ibagué 730001, Colombia
| | - Victoria Tapia
- Biology
Department, Faculty of Sciences, Universidad de Chile, Santiago 7800024, Chile
| | - Yorka Muñoz
- Biology
Department, Faculty of Sciences, Universidad de Chile, Santiago 7800024, Chile
| | - Bruce K. Cassels
- Department
of Chemistry, Faculty of Sciences, Universidad de Chile, Santiago 7800024, Chile
| | - Marco T. Núñez
- Biology
Department, Faculty of Sciences, Universidad de Chile, Santiago 7800024, Chile
| |
Collapse
|
7
|
Morse AC, Beard JL, Azar MR, Jones BC. Sex and Genetics are Important Cofactors in Assessing the Impact of Iron Deficiency on the Developing Mouse Brain. Nutr Neurosci 2016; 2:323-35. [DOI: 10.1080/1028415x.1999.11747287] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
8
|
Kim J, Wessling-Resnick M. Iron and mechanisms of emotional behavior. J Nutr Biochem 2014; 25:1101-1107. [PMID: 25154570 PMCID: PMC4253901 DOI: 10.1016/j.jnutbio.2014.07.003] [Citation(s) in RCA: 160] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2014] [Revised: 07/15/2014] [Accepted: 07/24/2014] [Indexed: 12/14/2022]
Abstract
Iron is required for appropriate behavioral organization. Iron deficiency results in poor brain myelination and impaired monoamine metabolism. Glutamate and γ-aminobutyric acid homeostasis is modified by changes in brain iron status. Such changes produce not only deficits in memory/learning capacity and motor skills, but also emotional and psychological problems. An accumulating body of evidence indicates that both energy metabolism and neurotransmitter homeostasis influence emotional behavior, and both functions are influenced by brain iron status. Like other neurobehavioral aspects, the influence of iron metabolism on mechanisms of emotional behavior is multifactorial: brain region-specific control of behavior, regulation of neurotransmitters and associated proteins, temporal and regional differences in iron requirements, oxidative stress responses to excess iron, sex differences in metabolism, and interactions between iron and other metals. To better understand the role that brain iron plays in emotional behavior and mental health, this review discusses the pathologies associated with anxiety and other emotional disorders with respect to body iron status.
Collapse
Affiliation(s)
- Jonghan Kim
- Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USA.
| | | |
Collapse
|
9
|
Chen MH, Su TP, Chen YS, Hsu JW, Huang KL, Chang WH, Chen TJ, Bai YM. Association between psychiatric disorders and iron deficiency anemia among children and adolescents: a nationwide population-based study. BMC Psychiatry 2013; 13:161. [PMID: 23735056 PMCID: PMC3680022 DOI: 10.1186/1471-244x-13-161] [Citation(s) in RCA: 97] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/11/2012] [Accepted: 05/28/2013] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND A great deal of evidence has shown that iron is an important component in cognitive, sensorimotor, and social-emotional development and functioning, because the development of central nervous system processes is highly dependent on iron-containing enzymes and proteins. Deficiency of iron in early life may increase the risk of psychiatric morbidity. METHODS Utilizing the National Health Insurance Database from 1996 to 2008, children and adolescents with a diagnosis of IDA were identified and compared with age and gender-matched controls (1:4) in an investigation of the increased risk of psychiatric disorders. RESULTS A total of 2957 patients with IDA, with an increased risk of unipolar depressive disorder (OR = 2.34, 95% CI = 1.58 ~ 3.46), bipolar disorder (OR = 5.78, 95% CI = 2.23 ~ 15.05), anxiety disorder (OR = 2.17, 95% CI = 1.49 ~ 3.16), autism spectrum disorder (OR = 3.08, 95% CI = 1.79 ~ 5.28), attention deficit hyperactivity disorder (OR = 1.67, 95% CI = 1.29 ~ 2.17), tic disorder (OR = 1.70, 95% CI = 1.03 ~ 2.78), developmental delay (OR = 2.45, 95% CI = 2.00 ~ 3.00), and mental retardation (OR = 2.70, 95% CI = 2.00 ~ 3.65), were identified. A gender effect was noted, in that only female patients with IDA had an increased OR of bipolar disorder (OR = 5.56, 95% CI = 1.98 ~ 15.70) and tic disorder (OR = 2.95, 95% CI = 1.27 ~ 6.86). CONCLUSION Iron deficiency increased the risk of psychiatric disorders, including mood disorders, autism spectrum disorder, attention deficit hyperactivity disorder, and developmental disorders. Further study is required to clarify the mechanism in the association between IDA and psychiatric disorder.
Collapse
Affiliation(s)
- Mu-Hong Chen
- Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Tung-Ping Su
- Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan,Department of Psychiatry, College of Medicine, National Yang-Ming University, Taipei, Taiwan
| | - Ying-Sheue Chen
- Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Ju-Wei Hsu
- Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Kai-Lin Huang
- Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Wen-Han Chang
- Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Tzeng-Ji Chen
- Department of Family Medicine, Taipei Veterans General Hospital, Taipei, Taiwan,Institute of Hospital and Health Care Administration, National Yang-Ming University, Taipei, Taiwan
| | - Ya-Mei Bai
- Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan,Department of Psychiatry, College of Medicine, National Yang-Ming University, Taipei, Taiwan
| |
Collapse
|
10
|
Carlson ES, Tkac I, Magid R, O'Connor MB, Andrews NC, Schallert T, Gunshin H, Georgieff MK, Petryk A. Iron is essential for neuron development and memory function in mouse hippocampus. J Nutr 2009; 139:672-9. [PMID: 19211831 PMCID: PMC2666361 DOI: 10.3945/jn.108.096354] [Citation(s) in RCA: 130] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Iron deficiency (ID) is the most prevalent micronutrient deficiency in the world and it affects neurobehavioral outcome. It is unclear whether the effect of dietary ID on the brain is due to the lack of neuronal iron or from other processes occurring in conjunction with ID (e.g. hypoxia due to anemia). We delineated the role of murine Slc11a2 [divalent metal ion transporter-1 (DMT-1)] in hippocampal neuronal iron uptake during development and memory formation. Camk2a gene promoter-driven cre recombinase (Cre) transgene (Camk2a-Cre) mice were mated with Slc11a2 flox/flox mice to obtain nonanemic Slc11a2(hipp/hipp) (double mutant, hippocampal neuron-specific knockout of Slc11a2(hipp/hipp)) mice, the first conditionally targeted model of iron uptake in the brain. Slc11a2(hipp/hipp) mice had lower hippocampal iron content; altered developmental expression of genes involved in iron homeostasis, energy metabolism, and dendrite morphogenesis; reductions in markers for energy metabolism and glutamatergic neurotransmission on magnetic resonance spectroscopy; and altered pyramidal neuron dendrite morphology in area 1 of Ammon's Horn in the hippocampus. Slc11a2(hipp/hipp) mice did not reach the criterion on a difficult spatial navigation test but were able to learn a spatial navigation task on an easier version of the Morris water maze (MWM). Learning of the visual cued task did not differ between the Slc11a2(WT/WT) and Slc11a2(hipp/hipp) mice. Slc11a2(WT/WT) mice had upregulation of genes involved in iron uptake and metabolism in response to MWM training, and Slc11a2(hipp/hipp) mice had differential expression of these genes compared with Slc11a2(WT/WT) mice. Neuronal iron uptake by DMT-1 is essential for normal hippocampal neuronal development and Slc11a2 expression is induced by spatial memory training. Deletion of Slc11a2 disrupts hippocampal neuronal development and spatial memory behavior.
Collapse
Affiliation(s)
- Erik S. Carlson
- Medical Scientist Training Program, Graduate Program in Neuroscience, Pediatrics, Center for Neurobehavioral Development, Center for Magnetic Resonance Research, and Genetics, Cell Biology and Development, University of Minnesota Medical School, Minneapolis, MN 55455; Howard Hughes Medical Institute, Chevy Chase, MD 20815; Duke University School of Medicine, Durham, NC 27710; Institute for Neuroscience, and Department of Psychology, University of Texas, Austin, TX 78712; and Department of Nutrition, University of Massachusetts, Amherst, MA 01003
| | - Ivan Tkac
- Medical Scientist Training Program, Graduate Program in Neuroscience, Pediatrics, Center for Neurobehavioral Development, Center for Magnetic Resonance Research, and Genetics, Cell Biology and Development, University of Minnesota Medical School, Minneapolis, MN 55455; Howard Hughes Medical Institute, Chevy Chase, MD 20815; Duke University School of Medicine, Durham, NC 27710; Institute for Neuroscience, and Department of Psychology, University of Texas, Austin, TX 78712; and Department of Nutrition, University of Massachusetts, Amherst, MA 01003
| | - Rhamy Magid
- Medical Scientist Training Program, Graduate Program in Neuroscience, Pediatrics, Center for Neurobehavioral Development, Center for Magnetic Resonance Research, and Genetics, Cell Biology and Development, University of Minnesota Medical School, Minneapolis, MN 55455; Howard Hughes Medical Institute, Chevy Chase, MD 20815; Duke University School of Medicine, Durham, NC 27710; Institute for Neuroscience, and Department of Psychology, University of Texas, Austin, TX 78712; and Department of Nutrition, University of Massachusetts, Amherst, MA 01003
| | - Michael B. O'Connor
- Medical Scientist Training Program, Graduate Program in Neuroscience, Pediatrics, Center for Neurobehavioral Development, Center for Magnetic Resonance Research, and Genetics, Cell Biology and Development, University of Minnesota Medical School, Minneapolis, MN 55455; Howard Hughes Medical Institute, Chevy Chase, MD 20815; Duke University School of Medicine, Durham, NC 27710; Institute for Neuroscience, and Department of Psychology, University of Texas, Austin, TX 78712; and Department of Nutrition, University of Massachusetts, Amherst, MA 01003
| | - Nancy C. Andrews
- Medical Scientist Training Program, Graduate Program in Neuroscience, Pediatrics, Center for Neurobehavioral Development, Center for Magnetic Resonance Research, and Genetics, Cell Biology and Development, University of Minnesota Medical School, Minneapolis, MN 55455; Howard Hughes Medical Institute, Chevy Chase, MD 20815; Duke University School of Medicine, Durham, NC 27710; Institute for Neuroscience, and Department of Psychology, University of Texas, Austin, TX 78712; and Department of Nutrition, University of Massachusetts, Amherst, MA 01003
| | - Timothy Schallert
- Medical Scientist Training Program, Graduate Program in Neuroscience, Pediatrics, Center for Neurobehavioral Development, Center for Magnetic Resonance Research, and Genetics, Cell Biology and Development, University of Minnesota Medical School, Minneapolis, MN 55455; Howard Hughes Medical Institute, Chevy Chase, MD 20815; Duke University School of Medicine, Durham, NC 27710; Institute for Neuroscience, and Department of Psychology, University of Texas, Austin, TX 78712; and Department of Nutrition, University of Massachusetts, Amherst, MA 01003
| | - Hiromi Gunshin
- Medical Scientist Training Program, Graduate Program in Neuroscience, Pediatrics, Center for Neurobehavioral Development, Center for Magnetic Resonance Research, and Genetics, Cell Biology and Development, University of Minnesota Medical School, Minneapolis, MN 55455; Howard Hughes Medical Institute, Chevy Chase, MD 20815; Duke University School of Medicine, Durham, NC 27710; Institute for Neuroscience, and Department of Psychology, University of Texas, Austin, TX 78712; and Department of Nutrition, University of Massachusetts, Amherst, MA 01003
| | - Michael K. Georgieff
- Medical Scientist Training Program, Graduate Program in Neuroscience, Pediatrics, Center for Neurobehavioral Development, Center for Magnetic Resonance Research, and Genetics, Cell Biology and Development, University of Minnesota Medical School, Minneapolis, MN 55455; Howard Hughes Medical Institute, Chevy Chase, MD 20815; Duke University School of Medicine, Durham, NC 27710; Institute for Neuroscience, and Department of Psychology, University of Texas, Austin, TX 78712; and Department of Nutrition, University of Massachusetts, Amherst, MA 01003
| | - Anna Petryk
- Medical Scientist Training Program, Graduate Program in Neuroscience, Pediatrics, Center for Neurobehavioral Development, Center for Magnetic Resonance Research, and Genetics, Cell Biology and Development, University of Minnesota Medical School, Minneapolis, MN 55455; Howard Hughes Medical Institute, Chevy Chase, MD 20815; Duke University School of Medicine, Durham, NC 27710; Institute for Neuroscience, and Department of Psychology, University of Texas, Austin, TX 78712; and Department of Nutrition, University of Massachusetts, Amherst, MA 01003
| |
Collapse
|
11
|
Connor JR, Wang XS, Neely EB, Ponnuru P, Morita H, Beard J. Comparative study of the influence of Thy1 deficiency and dietary iron deficiency on dopaminergic profiles in the mouse striatum. J Neurosci Res 2009; 86:3194-202. [PMID: 18615641 DOI: 10.1002/jnr.21758] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Thy-1, a glycosyl-phosphatidylinositol (GPI)-linked integral membrane protein, may play a role in stabilizing synapses. Thy1 was identified in a gene expression analysis as iron responsive, and subsequent cell culture and animal models of iron deficiency expanded this finding to the protein. The importance of Thy1 in influencing neurotransmitter feedback mechanisms led to this study to determine the relative effects of Thy1 deficiency and dietary iron deficiency on the dopaminergic system in the mouse striatum. The model for this analysis was the Thy1 null mutant mouse in the presence or absence of dietary iron deficiency. The results revealed significant differences in dopaminergic profiles associated with Thy1 and iron deficiency and also a sex effect. For example, both iron deficiency and the absence of Thy1 are associated with increased dopamine in both sexes, but the dopamine transporter is increased in these experimental groups only in female mice. In male mice, the increase in dopamine transporter is found only in the Thy1 null mutants. Increases in vesicular monoamine transporter and phosphorylated tyrosine hydroxlyase are found only in iron-deficient mice. In contrast decreased release of dopamine from synaptosomes is found only in the Thy1 null mutant animals. In general, these results indicate that a loss of Thy1 can influence the dopaminergic profile in the striatum. Furthermore, the results reveal consistent differences in the dopaminergic profile in Thy1 knockout mice compared with iron-deficient mice, indicating that the effects of iron deficiency are not due only to a change in Thy1 expression.
Collapse
Affiliation(s)
- James R Connor
- Department of Neurosurgery, MS Hershey Medical Center, Penn State College of Medicine, Hershey, PA 17033, USA.
| | | | | | | | | | | |
Collapse
|
12
|
Anderson JG, Fordahl SC, Cooney PT, Weaver TL, Colyer CL, Erikson KM. Manganese exposure alters extracellular GABA, GABA receptor and transporter protein and mRNA levels in the developing rat brain. Neurotoxicology 2008; 29:1044-53. [PMID: 18771689 DOI: 10.1016/j.neuro.2008.08.002] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2008] [Revised: 07/30/2008] [Accepted: 08/04/2008] [Indexed: 01/14/2023]
Abstract
Unlike other essential trace elements (e.g., zinc and iron) it is the toxicity of manganese (Mn) that is more common in human populations than its deficiency. Data suggest alterations in dopamine biology may drive the effects associated with Mn neurotoxicity, though recently gamma-aminobutyric acid (GABA) has been implicated. In addition, iron deficiency (ID), a common nutritional problem, may cause disturbances in neurochemistry by facilitating accumulation of Mn in the brain. Previous data from our lab have shown decreased brain tissue levels of GABA as well as decreased (3)H-GABA uptake in synaptosomes as a result of Mn exposure and ID. These results indicate a possible increase in the concentration of extracellular GABA due to alterations in expression of GABA transport and receptor proteins. In this study weanling-male Sprague-Dawley rats were randomly placed into one of four dietary treatment groups: control (CN; 35mg Fe/kg diet), iron-deficient (ID; 6mg Fe/kg diet), CN with Mn supplementation (via the drinking water; 1g Mn/l) (CNMn), and ID with Mn supplementation (IDMn). Using in vivo microdialysis, an increase in extracellular GABA concentrations in the striatum was observed in response to Mn exposure and ID although correlational analysis reveals that extracellular GABA is related more to extracellular iron levels and not Mn. A diverse effect of Mn exposure and ID was observed in the regions examined via Western blot and RT-PCR analysis, with effects on mRNA and protein expression of GAT-1, GABA(A), and GABA(B) differing between and within the regions examined. For example, Mn exposure reduced GAT-1 protein expression by approximately 50% in the substantia nigra, while increasing mRNA expression approximately four-fold, while in the caudate putamen mRNA expression was decreased with no effect on protein expression. These data suggest that Mn exposure results in an increase in extracellular GABA concentrations via altered expression of transport and receptor proteins, which may be the basis of the neurological characteristics of manganism.
Collapse
Affiliation(s)
- Joel G Anderson
- Department of Nutrition, University of North Carolina at Greensboro, Greensboro, NC 27402, USA
| | | | | | | | | | | |
Collapse
|
13
|
Agarwal KN. Iron and the brain: neurotransmitter receptors and magnetic resonance spectroscopy. Br J Nutr 2007. [DOI: 10.1079/bjn2000307] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
14
|
Wang X, Wiesinger J, Beard J, Felt B, Menzies S, Earley C, Allen R, Connor J. Thy1 expression in the brain is affected by iron and is decreased in Restless Legs Syndrome. J Neurol Sci 2004; 220:59-66. [PMID: 15140607 DOI: 10.1016/j.jns.2004.02.004] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2003] [Revised: 01/02/2004] [Accepted: 02/05/2004] [Indexed: 11/25/2022]
Abstract
Thy-1 is a cell adhesion molecule that plays a regulatory role in the vesicular release of neurotransmitters. The objective of this study is to examine the relationship between iron status and Thy1 expression in neuronal systems of varying complexity. Pheochromocytoma cell (PC12) cells were used to explore whether there was a direct relation between cellular iron status and Thy1 expression. Iron chelation significantly decreased expression of Thy1 in PC12 cells in a dose and time dependent manner. Transferrin receptor expression was increased with iron chelation demonstrating that a global decrease in protein synthesis could not account for the Thy1 changes. We also examined brain homogenates from adult rats that were nursed by dams on an iron deficient (ID) diet and found a significant decrease in Thy1 compared to control rats. Finally, the substantia nigra from individuals with Restless Legs Syndrome reportedly has lower than normal amounts of iron. Therefore, we examined this brain region from individuals with the clinical diagnosis of primary Restless Legs syndrome (RLS) and found the concentration of Thy1 was less than half that of controls. The results of these studies support the novel concept that there is a relationship between Thy1 and iron and point to a novel mechanism by which iron deficiency can affect brain function. They also indicate a possible mechanism by which iron deficiency compromises dopaminergic transmission in RLS, providing a potentially important link between decreased brain iron and the responsiveness to levodopa and iron supplementation treatment in RLS.
Collapse
Affiliation(s)
- Xinsheng Wang
- Department of Neural and Behavioral Science (H109), Penn State College of Medicine, 500 University Drive, Hershey, PA 17033, USA
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Abstract
Iron deficiency is a common disorder in pediatric patients. Although the most common manifestation is that of anemia, iron deficiency is frequently the source of a host of neurologic disorders presenting to general pediatric neurologic practices. These disorders include developmental delay, stroke, breath-holding episodes, pseudotumor cerebri, and cranial nerve palsies. Although frequent, the identification of iron deficiency as part of the differential diagnosis in these disorders is uncommon and frequently goes untreated. The purpose of the current review is to highlight what is understood regarding iron deficiency and it's underlying pathophysiology as it relates to the brain, and the association of iron deficiency with common neurologic pediatric disease.
Collapse
Affiliation(s)
- Jerome Y Yager
- Department of Pediatrics, University of Saskatchewan;, Saskatoon, Canada
| | | |
Collapse
|